Fedorov et al. constructed a PD-1 and cytotoxic T-lymphocyte-associated protein 4 (CTLA-4)-based iCAR-T and confirmed its selective and reversible suppression of T cell activity, which provides a dynamic safety switch to prevent potential on-target off-tumor effects [81]. Here, CTLA4 is linked to neoplasm.